E67-2 is a potent and selective inhibitor of H3K9 Jumonji demethylase KIAA1718 (KDM7A) with IC50 of 3.4 uM.

E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.

E-7050 is hepatocyte growth factor receptors (HGFR).

E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.

E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.

E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM).

E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM).

E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo.

E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively.

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells.

EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.

EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca

EB-3D is a novel potent and selective choline kinase ChoKα inhibitor with IC50 of 1.0 uM (purified ChoKα1), strongly impairs cell proliferation in a variety of different cancer cell lines.

EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.

EBI-1051 is a novel and orally efficacious MEK inhibitor with IC50 of 10.8 nM against MEK1, inhibits viability of colo-205 cells with IC50 of 4.7 nM.

EBI-2511 is a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma.

EBI-907 is a highly potent, selective, orally active B-Raf V600E inhibitor with enzyme IC50 of 7 nM, A375 cell growth IC50 of 13 nM.

Ebselen is a selenium-based inhibitor of protein kinase C, NADPH, 5-lipoxygenase, cyclooxygenase (COX) and NADPH oxidase.

EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC).

EC330 is a leukemia inhibitory factor (LIF) inhibitor.

EC-359 (EC359) is a first-in-class, orally available inhibitor of leukemia inhibitory factor (LIF), blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay.

EC-70124 is a multikinase inhibitor with potent activity against several AML related kinases including FLT3, JAK, SYK or Pim kinases (Kd<10 nM).

Ecabet is an antiulcerative and gastroprotective agent.

Ecdysone

Echinocandin B0

Echinocystic acid  a pentacyclic triterpene isolated from the fruits of Gleditsia sinensis Lam, has potent antioxidant, anti-inflammatory and anti-tumor properties.

Econazole nitrate (Spectazole)

Ecopladib (PLA 725) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 0.15 and 0.11 uM in GLU micelle and rat whole blood assays, respectively.

Ecteinascidin 770 (ET-770) is a 1,2,3,4-tetrahydroisoquinoline alkaloid with potent anti-cancer activities; inhibits U373MG cells with an IC50 of 4.83 nM.

Edaravone (MCI-186)

Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).

Edelfosine is a synthetic lysophospholipid analog that selectively inhibits PLC with IC50 of 9.6 uM in fibroblasts and adenocarcinoma cells.

Edicotinib（JNJ-40346527）is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity.

Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD)..

Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD)..

Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention

Efaproxiral Sodium is a synthetic allosteric modifier of hemoglobin, used for brain metastases originating from breast cancer.

Efavirenz is a nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor which selectively inhibits the glucuronidation of 3'-Azido-3'-deoxythymidine β-D-glucuronide, Sodium Salt. Studies suggest that Efavirenz binds to a distinct site of reverse transcrip

Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis.

Efipladib (PLA 902) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 20 nM for LTB4 inhibition.

Eflornithine(Difluoromethylornithine) inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis. Its biological half-life is 8 hours.

Efonidipine(NZ-105) Hcl monoethanolate is a dual T-type and L-type calcium channel blocker (CCB).

eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

EG00229 is a specific inhibitor of neuropilin-1 (NRP1)/VEGF-A interaction, inhibits the binding of biotinylated VEGFA to NRP1 with IC50 of 8 uM.

EG01377 is a potent and bioavailable inhibitor of the NRP1/VEGF-A interaction (Kd=1.32 uM), selective for NRP1 over the closely related protein NRP2.

Eg5 Inhibitor III, Dimethylenastron is a cell-permeable quinazoline-thione compound that acts as a strong, specific, and reversible inhibitor of the microtubule-stimulated ATPase activity of the mitotic motor, Eg5.

Eg5 Inhibitor V, trans-24 is a potent and specific Eg5 inhibitor with an IC50 of 0.65 μM, and can be used in the research of cancer.

EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.

EGFR-IN-99 (compound 1a) is a potent EGFR and HER2 Exon 20 insertion mutant inhibitor. EGFR-IN-99 has excellent antiproliferative activity against DFCI127 cells, with an EC50 of 11.5 nM. EGFR-IN-99 can be used for the research of non-small cell lung cancer (NSCLC).

Eggmanone is a potent, selective inhibitor of PDE4 with (IC50=72 nM) that antagonizes the Hedgehog signaling pathway.

EHop-016 is a novel inhibitor of Rac GTPase with IC50 of 1.1 μM for Rac1, equally potent inhibition for Rac3.

EHT 1864 is a potent Rac family GTPase inhibitor with Kd of 40 nM, 50 nM, 60 nM and 250 nM for Rac1, Rac1b, Rac2 and Rac3, respectively.

EHT 5372 is a novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

EI1 is a potent and selective small molecule inhibitor of EZH2 with IC50 values of 15 nM and 13 nM for wild type EZH2 and EZH2 Y641F mutant, respectively.

Eicosadienoic acid is a rare, naturally occurring n-6 polyunsaturated fatty acid found mainly in animal tissues.

eIF4A3 inhibitor 53a is a potent, selective and cell-active eukaryotic initiation factor 4A3 (eIF4A3) inhibitor with IC50 of 0.26 uM, SPR Kd of 43 nM.

eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM.

EL-102 is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade.

Elacestrant dihydrochloride (RAD1901 dihydrochloride) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.

Elacestrant S enantiomer is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.

Elacridar is an orally selectly potent P-glycoprotein (P-gp/ABCG1) inhibitor.

Elacytarabine (CP-4055, CP4055) is a fatty acid derivative of cytarabine with potential antineoplastic activity.

Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.

Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist.

Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist.

Elaiophylin (Gopalamicin.

Elatol (NSC 341593) is a specific inhibitor of ATP hydrolysis by eIF4A1 in vitro with broad activity against multiple tumor types.

Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficaci

Eleclazine(GS-6615) is a selective late sodium current inhibitor.

Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease..

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells..

Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist.

Eletriptan HBr is an orally active, selective 5-HT1B/1D receptor agonist.

Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.

Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.

Elinogrel is a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events.

Eliprodil is a non-competitive NMDA receptor antagonist that acts at the polyamine modulatory site.

Ellipticine hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities.

Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor.

ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.IC50 value: 0.26 nM (Ki)Target: B1 Receptorin vitro: ELN-441958 is a novel small molecule bradykinin B1 receptor antagonist, based on the inhibition of agonist-induced increases in intracellular calcium in native and recombinant cells. ELN-441958 does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM, showing that it is highly selective for B1 over B2 receptors. ELN-441958 also displays good selectivity for B1 over other receptors examined in a broad screening panel. It is >500-fold and >2000-fold selective for the B1 receptor over the human μ- and δ-opioid receptor, the most potent off-target activity identified. In IMR-90 cells expressing the native human B1 receptor, ELN-441958 produced a concentration-dependent antagonism of the DAKD-induced calcium mobilization with a KB of 0.12 nM. [1]in vivo: ELN-441958 is essentially completely absorbed and produces high plasma levels after oral administration in rhesus monkeys.ELN-441958 has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. ELN-441958 has high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. The oral availability of ELN441958 in rats was 57%. ELN-441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 3 mg/kg s.c. [1]

ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.

ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease.

Elocalcitol

ELQ300 is a novel inhibitor of the mitochondrial cytochrome bc1 complex (complex III in the electron transport chain).

Eltrombopag (SB-497115-GR)

Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.

Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

Elubrixin (SB-656933, GSK-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

Eluxadoline Dihydrochloride is an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist.

Eluxadoline is an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist.

Elvitegravir (EVG) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor.

EMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over AT1 receptor, produces analgesia in rodent model of neuropathic pain..

EMA400 is a potent and highly selective AT2R antagonist.

EMA401(Olodanrigan) is a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.

Emamectin Benzoate works as a chloride channel activator by binding gamma aminobutyric acid (GABA) receptor and glutamate-gated chloride channels disrupting nerve signals within arthropods.

Emapunil(AC-5216;XBD-173) is a translocator protein

EMD-281014 hydrochloride is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels.

EMD-281014 is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels.

EMD534085 is a kinesin inhibitor currently in clinical development.

EMD638683 is a potent SGK1 inhibitor with an IC50 of 3 uM.

EMICORON is a novel G-quadruplex (G4) ligand showing high selectivity for G4 structures over the duplex DNA, causing telomere damage and inhibition of cell proliferation in transformed and tumor cells.

Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM.

Emixustat, a novel visual cycle modulator, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro.

EML-405 (EML405) is a small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 14 uM.

Emodepside (PF 1022-221) is a cyclooctadepsipeptide with broad-spectrum anthelmintic activity.

Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in

Empesertib (BAY-1161909, BAY1161909) is a potent, selective Monopolar spindle 1 (Mps1/TTK) inhibitor with IC50 of 0.34 nM.

Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase inhibitor.

EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.

Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reve

EN460 is a specific mall molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1), interacts selectively with the reduced, active form of ERO1α and prevents its reoxidation (IC50=1.9 uM).

EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase, which activates mTORC1 via the Rag guanosine triphosphatases.

Enadoline (CI 977.

Enalapril maleate (Vasotec)

Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes.

Endoxifen (E-isomer hydrochloride) is a tamoxifen metabolite and potent Selective Estrogen Response Modifier (SERM).

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.

Endoxifen is a Estrogen receptor α (ERα) ligand; potent antiestrogen,an active metabolite of the cancer drug tamoxifen.

Eniporide is a The Na(+)/H(+) exchange inhibitor.

ENMD-1068 is a novel selective PAR2 antagonist without inhibitory activity against thrombin-mediated PAR3 and PAR4 signaling.

ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα.

ENOblock Hcl(AP-III-a4 Hcl) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.

ENOblock(AP-III-a4) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.

Enocitabine is an anti-tumor agent and an antineoplastic. A derivative of Cytarabine.

Enocyanin is an anthocyanin extracted from grapes. Enocyanin shows inhibitory effect on the leucine aminopeptidase, acid phosphatase, γ-glutamyl transpeptidase and esterase activity.

Ensartinib is a potent inhibitor of ALK, which is used to treat non-small-cell lung cancer.

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.

Entecavir hydrate belongs to the family of medicines called antivirals.

Entecavir is a deoxyguanosine nucleoside analogue with antiviral activity against the hepatitis B virus (HBV).

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 1/2.

Ent-kaurene is a tetracyclic diterpene consisting of ent-kaurane, where the 6-methyl group is replaced by methylene. It derives from a hydride of an ent-kaurane.

Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions.

Enviroxime (Zinviroxime.

Enzaplatovir (BTA-585, BTA-C585) is an orally bioavailable RSV fusion protein inhibitor for the treatment of respiratory syncytial virus infections..

Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.

EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor with increased aqueous solubility and greater cellular Usp9x inhibitory activity than WP1130.

Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM. Phase 2.

Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.

Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.

EphB3-IN-1 is the first potent, selective inhibitor of EphB3 that exhibits inhibiting EphB3 autophosphorylation in cells with IC50 of 3 nM.

EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ∼6 μM and a selective PPAR-gamma modulator

EPI-743 (Vatiquinone,EPI-589) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone.

Epiandrosterone is a steroid hormone with weak androgenic activity. Epiandrosterone is naturally produced by the enzyme 5α-reductase from the adrenal hormone DHEA.

Epibrassinolide (EBR; B1105; 24-Epibrassinolide) is a biologically active compound of the brassinosteroids, steroid-derived plant growth regulator family; was shown as a potential apoptotic inducer in various cancer cells without affecting the non-tumor c

Epigoitrin and fructopyrano-(1→4)-glucopyranose(FG) from the traditional Chinese medicine Isatidis radix, exhibit in vitro cooperation, they have in vitro anti-virus activity.

Epinastine(WAL801) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.

Eplerenone, also known as Inspra and CGP-30083, is a selective aldosterone receptor antagonist used to treat hypertension and congestive heart failure. Eplerenone provides marked protection against vascular injury in the kidney and heart.

Epolactaene is a neuritogenic fungal isolate that arrests the cell cycle at the G0/G1 phase and induces the outgrowth of neurites in human neuroblastoma SH-SY5Y cells.

Epothilone A is a Taxol-like microtubule-stabilizing agent that induces tubulin polymerization, leading to cell cycle arrest at the G2-M transition, cytotoxicity, and apoptosis.

Epothilone B is a Taxol-like microtubule-stabilizing agent with EC0.01 of 1.8 μM.

Epothilone D(Desoxyepothilone B; KOS 862) is a natural polyketide compound isolated from the myxobacterium Sorangium cellulosum.

Epoxomicin is a selective and irreversible inhibitor of 20S proteasome with an IC50 value of 4 nM.

Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.

Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.

Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family.

EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM.

EPZ-005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.

EPZ011989 is a potent, orally-available EZH2 Inhibitor.

EPZ015666 is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs.

EPZ015866(GSK591) is a potent, selective PRMT5 inhibitor.

EPZ019997 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)).

EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has ＞10 fold selectivity for PRMT6 over PRMT1 and PRMT8.

EPZ020411 is a potent, selective PRMT6 inhibitor with IC50 of 10 nM, displays 10-fold and 20-fold selectivity over PRMT1/8, and >100-fold over other histone methyltransferases (PRMT3/4/5/7).

EPZ020411 is a potent, selective PRMT6 inhibitor with IC50 of 10 nM, displays 10-fold and 20-fold selectivity over PRMT1/8, and >100-fold over other histone methyltransferases (PRMT3/4/5/7).

EPZ025654 (GSK 35336023) is a potent, selective arginine methyltransferase CARM1 inhibitor with IC50 of 3 nM.

EPZ-030456 (EPZ030456) is a potent, selective SMYD3 inhibitor with biochem IC50 of 4 nM.

EPZ031686 is a noncompetitive inhibitor for SMYD3 and MEKK2 with a Ki=1.2 and 1.1 nM respectively.

EPZ-5676 is a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity.

EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity with Ki value of 2.5±0.5 nM.

Equisetin is an N-methylserine-derived acyl tetramic acid produced by a number of Fusarium species with antibiotic and cytotoxic activity.

ER-000444793 is a potent, cyclophilin D-independent inhibitor of mitochondrial permeability transition pore (mPTP) with with IC50 of 2.8 uM.

ER-27319 maleate is a potent, selective inhibitor of antigen or anti-IgE-mediated degranulation of rodent and human mast cells by selective inhibition of FcɛRI-mediated activation of Syk.

ER-464195-01 is a specific, orally active inhibitor that inhibits Calreticulin (CRT) binding to integrin α subunits (ITGAs) with IC50 of 0.17, 0.36, and 0.23 uM in the interaction between CRT and ITGA α4, αL, and αM/α2/α5.

ER-819762 is a novel potent, selective, orally active EP4 receptor antagonist with IC50 of 59 nM in cAMP-dependent reporter assay.

Erastin is a compound that interacts with VDAC, blocked and reversed mitochondrial depolarization after microtubule destabilizers in intact cells and antagonized tubulin-induced VDAC blockage in planar bilayers.

ERD03 (EXOSC3-RNA disrupting compound 3) is a small molecule EXOSC3-RNA disrupting (ERD) compound that binds specifically to EXOSC3 (Kd=17 uM), induces a PCH1B-like phenotype in zebrafish.

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively.

Erdosteine

ERGi-USU (NSC139021) is a small molecule that selectively inhibits ERG-positive cancer cell growth (VCaP cell IC50=0.169 uM), directly binds the ribosomal biogenesis regulator atypical kinase RIOK2 and induces ribosomal stress signature.

Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.

Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma.

Eribulin Mesylate (E7389 Mesylate), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules.

Eritoran tetrasodium (E5564) is an investigational drug for the treatment of severe sepsis that acts as a TLR4 antagonist..

ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively.

Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.

Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz.

Ertapenem Sodium

Erythromycin Cyclocarbonate, derivative of Erythromycin, inhibits protein synthesis of bacteria by binding to the 50S ribosome.

Erythromycin, an oral macrolide antibiotic produced by Streptomyces erythreus, reversibly binds to the 50S ribosome of bacteria, and inhibits protein synthesis.

ES9-17 is a novel CME inhibitor.

Escin is a mixture of saponins with anti-inflammatory, vasoconstrictor and vasoprotective effects found in Aesculus hippocastanum(the horse chestnut).

Escitalopram Oxalate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.

ESI-05 is a potent EAPC2-specific antagonist that inhibits cAMP-mediated EPAC2 GEF activity with apparent IC50 of 0.43 uM.